Knight is a multinational specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canada and Latin America.
Ms. Sakhia joined Knight as President in August 2016, was named President & Chief Operating Officer in June 2020 and assumed the role of President & Chief Executive Officer on September 1, 2021. Additionally, Ms. Sakhia served as CFO from October 2017 to March 2020. Prior to Knight, Ms. Sakhia served as the CFO at Paladin from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo International for $3.2 billion. Ms. Sakhia serves on the board of the Montreal Society for the Prevention of Cruelty to Animals, the International Advisory Board of McGill’s Desautels Faculty of Management, and is a member at large of the Board of Governors of McGill University and an independent Board member at the McGill University Health Center. Ms. Sakhia holds an MBA, a Bachelor of Commerce and a Graduate Diploma in Accountancy from McGill University.
Ms. Khouri joined Knight as Vice-President of Business Development in August 2014 and was promoted to Chief Business Officer in March 2021. At Knight, Ms. Khouri leads the corporate and business development teams as well as corporate strategy. Ms. Khouri was a key player in the acquisition of Grupo Biotoscana in 2019 and led the mandatory tender offer process that successfully completed in 2020. Prior to Knight, Ms. Khouri worked at Novartis Pharma for over 7 years, where she held multiple positions within the global business development and licensing team in Basel, Switzerland. Ms. Khouri worked on several transactions including product divestments, strategic projects as well as in-licensing opportunities. Before joining Novartis, Ms. Khouri worked in business development at Paladin Labs in roles with increasing responsibilities. In addition, Ms. Khouri serves on the board of Antibe Therapeutics. Ms. Khouri holds a B.Sc. in Biochemistry from McGill University and an M.B.A. from the University of Ottawa.
Mr. Utchanah joined Knight as Director of Finance in June 2016 and was promoted to Vice-President of Finance in August 2019 and Chief Financial Officer in March 2020. At Knight, Mr. Utchanah is responsible for managing the finance and treasury functions as well as supply chain operations and IT. Mr. Utchanah played a key role in the acquisition of Grupo Biotoscana in 2019. Prior to joining Knight, Mr. Utchanah held a number of senior finance roles with increasing responsibilities with Paladin Labs Inc., most recently as Director of Finance, Accounting and Financial Planning & Analysis where he was instrumental in the integration with Endo Health Solutions Inc. Mr. Utchanah’s move to Paladin Labs Inc. in 2012 after having spent 5 years with the global public accounting firm, Ernst & Young LLP, within the assurance services group. Mr. Utchanah is a Chartered Professional Accountant; he holds a Bachelor of Commerce degree from McGill University and a Graduate Diploma in Public Accountancy from Concordia University.
Mr. Martens joined Knight as Vice President, Commercial in October 2020. Prior to joining Knight, Mr. Martens was president and owner of Compass Healthcare Strategies which supported commercial efforts of health science companies in Canada and Latin America. Mr. Martens held a number of executive roles at Novartis including VP of Neuroscience Canada, VP of Immunology & Dermatology Canada, Business Unit Head of Ophthalmology Australia/NZ and Head of Marketing Oncology Canada. During Mr. Martens’ 7 years as an executive at Novartis, he had extensive experience in new product launches, and commercializing products in highly competitive specialty markets. Mr. Martens has over 20 years in the pharmaceutical space with a broad level of experience in multiple roles in addition to his executive level experience, including market access, marketing management, sales and sales management. Mr. Martens has an Honours, Bachelor of Science, specialized in Biophysics with a minor in Neuroscience from University of Guelph.
Ms. Emblem joined Knight in October 2020 and was named Global Vice President Human Resources in August 2021. At Knight, Ms. Emblem is responsible for leading all HR integration and HR strategy across the business. Prior to joining Knight, Ms. Emblem worked at Paladin Labs for 20 years, where she held a number of leadership roles including as Vice President, Human Resources & Corporate Communications. Ms. Emblem was also Marketing Director, where she launched several key brands across several therapeutic areas for the business. Prior to her time at Paladin, Ms. Emblem was Marketing Manager for MSN Australia and she also held brand management roles at Unilever Australia. Ms. Emblem currently serves as Vice Chair of the Board of Governors for Marianopolis College. Ms. Emblem has a Bachelor of Commerce with concentrations in International Business and Entrepreneurship from McGill University.
Monica has nearly 30 years of experience in the pharmaceutical industry. Prior to joining Knight, Mrs. Percario was at Sanofi in Brazil where she had been working since 2008, most recently as Head of Regulatory – LatAm and Center of Expertise LatAm. At Sanofi, she also participated in the integration of Aventis with Medley and developed a strong expertise in the generics market as well as mature products. Further, she implemented a regional regulatory function with teams in several countries in Latin America, including Brazil, Colombia, Peru, Mexico, Chile, Argentina and several other countries, resulting in agility and efficiency across multiple dossiers. Prior to Sanofi, Monica worked in various regulatory roles at Farmasa (now a part of Hypera Pharma). During her time at Farmasa, she created the pharmacovigilance department and participated in clinical research studies in the development of biological products.
Ms. Marino has over 20 years of experience in the legal field, in legal practice and the pharmaceutical industry. Prior to joining Knight, Ms. Marino was at Bausch Health in Brazil where she has been working since 2013, most recently as Head of Legal and Compliance – Latin America. At Bausch, she has been responsible for all activities carried out by the legal and compliance department in Latin America, including (i) support for a diversified range of business units including, pharmaceutical, surgical, vision care and consumer goods; (ii) support to both local and corporate business teams for the assessment of legal implications related to complex business matters; (iii) coordination of all activities related to the legal department, on both consulting and litigation areas, including Corporate Law, Labour, Tax, Criminal, Regulatory, Antitrust and Intellectual Property matters; and (iv) management of all activities related to the compliance area. Prior to Bausch, Ms. Marino spent many years at Ulhôa Canto, Rezende e Guerra Advogados, a specialty law firm in São Paulo where she advised clients on mergers and acquisitions, corporate reorganizations and deal negotiations. Ms. Marino holds a Bachelor of Law from University of the State of São Paulo, as well as a Specialization in Administrative Law and a Specialization in Business Law from Fundação Getúlio Vargas Law School.
Mr. Bosano has nearly 30 years of experience in operations management including over 25 years in the pharmaceutical industry. Prior to joining Knight, Mr. Bosano was at Givaudan Argentina where he had been working since 2014, most recently as Head of Operations – LatAm. At Givaudan, he was responsible for production, quality control and quality assurance, supply chain, engineering and maintenance across seven sites located in Argentina, Chile, Brazil, Colombia and Mexico. Prior to Givaudan, Mr. Bosano worked at HLB Pharma Group where he was Industrial Operations Director. In addition, he worked as General Manager and VP at UV-Vis Metrolab S.A. in Argentina. Prior to these roles, Mr. Bosano was at Bristol Myers Squibb for many years in Argentina as well as in Panama, where he held several roles including, planning, supply chain, procurement, technical operations, plant management and GM for supply to Middle and Far East and Latin American markets. Mr. Bosano holds a Bachelor of Chemical Engineering from Universidad Tecnológica Nacional as well as graduate degree in Marketing and Finance from Universidad Católica de la Plata.
Mr. Goodman founded Knight in February 2014 and was Knight’s CEO until September 1, 2021. Mr. Goodman was co-founder and President and CEO of Paladin Labs Inc. until its acquisition by Endo in 2014 for $3.2 billion. Under Mr. Goodman’s leadership, Paladin grew to be a leading Canadian specialty pharmaceutical company with sales of over $150 million in Canada. Prior to co-founding Paladin Labs Inc. in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University.
Mr. Gale is the founding partner of Signet Healthcare Partners (“Signet”). He is currently the Chairman of the Board of Alpex Pharma S.A. and Teligent Inc., and also serves on the board of directors of Spepharm BV, Bionpharma Inc., CoreRx, Inc., RK Pharma Inc., Leon Nanodrugs GmbH, Pharmaceuticals International Inc. and Chr. Olesen Synthesis A/S. Prior to Signet, Mr. Gale worked for Gruntal & Co., LLC (“Gruntal”) as head of principal investment activities and investment banking. Prior to joining Gruntal, he worked in Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co. Mr. Gale holds an M.B.A. from the University of Chicago. Mr. Gale was on the Board of Paladin Labs from 2008 to 2014.
* Member of the Audit Committee
Ms. Sakhia joined Knight as President in August 2016, was named President & Chief Operating Officer in June 2020 and assumed the role of President & Chief Executive Officer on September 1, 2021. Additionally, Ms. Sakhia served as CFO from October 2017 to March 2020. Prior to Knight, Ms. Sakhia served as the CFO at Paladin from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo International for $3.2 billion. Ms. Sakhia serves on the board of the Montreal Society for the Prevention of Cruelty to Animals, the International Advisory Board of McGill’s Desautels Faculty of Management, and is a member at large of the Board of Governors of McGill University and an independent Board member at the McGill University Health Center. Ms. Sakhia holds an MBA, a Bachelor of Commerce and a Graduate Diploma in Accountancy from McGill University.
Mr. Lande is the President of FXCM Group LLC, an online brokerage firm offering trading in foreign exchange, equity indices and commodities. Formerly, he was Chief Financial Officer of FXCM and prior to that was a managing partner and Chief Operating Officer of Riveredge Capital Partners LLC (“Riveredge”), an investment management firm. Prior to Riveredge, Mr. Lande worked for over 16 years within the BCE/Bell Canada group where his last position was Chief Financial Officer of Telecom Américas Ltd., a joint venture between Bell Canada International, AT&T (then SBC Communications) and America Movil. Mr. Lande was on the board of directors of Paladin Labs Inc. from 1995 to 2014. Mr. Lande is a chartered financial analyst and holds an M.B.A. from the John Molson School of Business and a B.A. in Economics from McGill University.
* Member of the Audit Committee
† Member of the Compensation, Corporate Governance and Nominating Committee
Mr. Tremblay has over 40 years of experience in the pharmaceutical industry. In 2018, he retired from Astellas Pharma Canada, Inc. where he served as President of Canadian operations. He joined the company in June 2000 and held various positions within the organization’s commercial area before being appointed to the President’s position in 2010. Prior to joining Astellas, Mr. Tremblay held positions at Janssen Canada Inc., Searle Canada Inc., Baxter-Travenol Canada and Smith, Kline and French Canada. Mr. Tremblay has sat on a number of Boards including Community & Home Assistance to Seniors (“CHATS”) and Innovative Medicines Canada (“IMC”), the organization representing the leading research-based pharmaceutical companies in Canada. Mr. Tremblay began serving on the Board at IMC in 2011 and was elected Chair of the Board in 2015 and held that position until November 2017. Mr. Tremblay holds a B.Sc. in Biology and Chemistry from the University of Windsor.
† Member of the Compensation, Corporate Governance and Nominating Committee
Mr. Sujoy has more than 20 years of private equity experience in Latin America. He was a member of Biotoscana Investments S.A.’s board of directors. He is a founding partner of the Private Equity firm Clara Capital. Formerly, Mr. Sujoy worked for Advent International where he was a director and country manager, participating in transactions in the pharma, banking and business services sectors, and serving on the Board of Directors of several companies. With Advent, where he worked for 7 years, Nicolás led or co-led investments in Nuevo Banco Comercial and Pronto in Uruguay, and in Laboratorios LKM and Fada Pharma in Argentina, among others. He also participated in the acquisition of Biotoscana Farma in Colombia, and the assembly of the regional pharmaceutical company GBT. Prior to joining Advent, he was an investment manager at HSBC Private Equity Latin America, where he participated in transactions in telecommunications and energy sectors, among others. Mr. Sujoy has been member of the board of Biotoscana Investments S.A. since May 2017. Mr. Sujoy holds a degree in economics from the Torcuato di Tella University in Argentina.
† Member of the Compensation, Corporate Governance and Nominating Committee
Ms. Murray has a wealth of pharmaceutical experience as well as leadership in general management, strategy, finance and sales & marketing. She served as the CFO of Novartis Pharmaceuticals Canada Inc., for several years before becoming Vice-President of the Ophthalmics Business Franchise. Ms. Murray then became the CFO of the Latin America & Canada Region responsible for 10 reporting units and $2B in sales. Before her retirement in 2019, she became President of Novartis Pharmaceuticals Canada Inc. leading multiple therapeutic areas, launching several innovative medicines and serving on the Innovative Medicines Canada Industry Board. Prior to working at Novartis, Ms. Murray held several roles at Canadian National Railways, including Vice-President Network Strategy Development, Vice-President of Sales and Market Development and Chief of Internal Audit where she led several strategic projects during key acquisitions and privatization. She completed her CPA, CA designation while working at KPMG where she became an Audit Manager. Ms. Murray holds a Bachelor of Commerce from University of Ottawa and a Graduate Diploma in Accounting from McGill University. Ms. Murray serves on the boards of Boondoc Technologies, the VOBOC Foundation, and the Teresa Dellar Palliative Care Residence Foundation. Ms. Murray holds a CPA designation from the Ordre des Comptables Professionnels Agréés du Quebec, as well as ICD.D designation from the Institute of Corporate Directors’ program at the University of Toronto – Rotman School of Management.
* Member of the Audit Committee
† Member of the Compensation, Corporate Governance and Nominating Committee
© 2023 All rights reserved | Knight Therapeutics Inc. Privacy Policy Whistleblower Code of Business Conduct and Ethics
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue
You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Click here to continue